Egis competitive analysis

Explore patent oppositions filed by Egis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jan 29, 2026
Patent NumberTitleApplicantOpposition Date
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025
New UseNOVARTISJul 8, 2024
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISOct 9, 2023
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 11, 2023
Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICADec 31, 2021
Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIMAug 12, 2019

Explore Egis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jan 29, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jan 8, 2020Compositions Comprising Amlodipine And Bisoprolol1
May 1, 2019Compositions Comrrising Amlodipine And Bisoprolol1

Latest PTAB cases involving Egis

Discover the latest PTAB cases involving Egis, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Egis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jan 29, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
UNILEVER6201 - -
DALLI WERKE6310 - -
HENKEL6031921 -
THE PROCTER & GAMBLE166384 - 21